Platelet adhesion is a complex and important event for prevention of blood loss after vessel injury. This study investigated fundamental adhesive mechanisms occurring in an in-vitro assay developed for the measurement of static adhesion of human platelets in plasma. The aim was to gain methodological knowledge that could be used for interpretations of results from other studies using this specific assay. Involvement of adhesive receptors was investigated by the use of various antibodies as well as therapeutic drugs (abciximab, eptifibatide and tirofiban). Inhibitors of adenosine 5 0 -diphosphate receptors (cangrelor, MRS2179) and of thromboxane A 2 signalling (BM-531) were used to estimate the role of autocrine activation. Adhesion to collagen was found to be mainly mediated by a 2 b 1 and to some extent by a IIb b 3 . Adhesion to fibrinogen was mediated by a IIb b 3 . In addition, adenosine 5 0 -diphosphate-induced adhesion to albumin was dependent on a IIb b 3 . Furthermore, experiments with cangrelor and BM-531 showed that the majority of the adhesive interactions tested were dependent on adenosine 5 0 -diphosphate or thromboxane A 2 . We conclude that the mechanisms of adhesion measured by the static platelet adhesion assay are in accordance with the current knowledge regarding platelet activation and adhesion. Despite its simplicity, we suggest that this adhesion assay could be used as a screening device for the study of the influence of various surfaces and soluble substances on platelet adhesion.
Introduction
Platelet adhesion is an important initial event in primary haemostasis. Consequently, a lot of research has been performed to investigate which platelet receptors are involved in this complex process. An important part of the extracellular matrix of blood vessels consists of collagen [1] , which acts as an attachment surface for platelets in wounded vessels. Platelet receptors for collagen include the a 2 b 1 -integrin [2] [3] [4] and the glycoprotein VI (GPVI) receptor belonging to the immunoglobulin receptor family [5] . It is generally accepted that a 2 b 1 primarily acts as an adhesive receptor for collagen, whereas GPVI is responsible for platelet activation [6, 7] . Another structure important for platelet adhesion is the platelet receptor GPIb-IX-V, which binds subendothelial von Willebrand factor (vWf) during conditions of high shear stress [8] . Finally, the a IIb b 3 -integrin present on platelets is also of importance for the haemostatic process. a IIb b 3 binds an Arg-Gly-Asp-sequence (RGD) present in several different proteins such as fibronectin, laminin and fibrinogen [9] . Interactions between a IIb b 3 and fibrinogen are especially important as they result in platelet aggregation [10] . It is clear that the adhesive process is dependent on different contributions from the different receptors. In general, temporary interactions between GPIb-IX-V and vWf support a rolling phenom-enon, which allows binding of GPVI to collagen [7] . The GPVI-collagen interaction as well as thrombin from plasma and substances such as adenosine 5 0 -diphosphate (ADP) and thromboxane A 2 (TXA 2 ) released from platelets, all contribute to platelet activation. Furthermore, firm adhesion to collagen is achieved by a 2 b 1 . The details of the process during flow conditions in vivo, especially regarding the relative contributions from a 2 b 1 and GPVI, are debated. An early model suggested that the initial interaction between platelets and collagen occurs through the a 2 b 1 -receptor [11] . However, the second model claims that initial interaction between GPVI and collagen must occur in order for a 2 b 1 to be activated and to be able to support firm adhesion [12] . Finally, a third model combines the previous two by assuming that some platelets act according to the first model and some according to the second [13] . This study investigated the adhesive mechanisms occurring in a modified version of the assay described by Bellavite et al. [14] , further developed for measuring adhesion of platelets in plasma to protein surfaces in microplates [15] . This assay is simple to use and, as it is performed in 96-well microplates, it is well suited for screening purposes in order to measure several aspects of platelet function simultaneously. The assay has earlier been used for investigation of platelet activity both in basic studies [16, 17] and in clinical research [18, 19] . The aim of this study was to investigate fundamental adhesion events occurring in this particular assay. Such methodological knowledge is always necessary when trying to interpret laboratory results. In this assay, platelets are added as platelet-rich plasma (PRP), which makes it especially important to investigate whether platelets adhere to the coated protein or if the surface is influenced by plasma proteins.
Methods

Blood sampling
Blood was collected consecutively from healthy blood donors at the Blood Transfusion Centre, University Hospital, Linkö ping, Sweden. The study conforms to the Declaration of Helsinki (1975) and later revisions and was approved by the local ethics committee. Only blood from donors declaring that they had not used any antiplatelet medication for 2 weeks prior to the study was used. Donors were also included only if they declared that, during the previous 3 months, they had not suffered fever after visiting malaria region; suffered medical treatment-required conditions; been pregnant; used acupuncture, tattoo or piercing; been treated by dentist the previous 14 days; or had been vaccinated or suffered infection the previous month. Blood was drawn into two 6 ml sodium heparin tubes for each donor. Thereafter, 8 ml of blood was transferred to a single plastic centrifuge tube and centrifuged for 20 min at 220 g. Approximately, two-thirds of the PRP in the supernatant was then removed and diluted four times with 0.9% NaCl. Dilution was necessary as undiluted plasma interferes with the below-described spectrophotometric measurements of platelet amount [15] .
Microplate coating
Ninety-six well microplates (Nunc Maxisorp, Roskilde, Denmark) were coated by the addition of 100 ml/well of 2 mg/ml human albumin (Octapharma AB, Stockholm, Sweden), 0.1 mg/ml bovine collagen I (RnDSystems, Abingdon, UK) or 2 mg/ml human fibrinogen (American Diagnostica, Inc., Greenwich, Connecticut, USA). The microplates were then left at 48C at least overnight but for a maximum of 7 days to allow protein adsorption to the wells.
Static platelet adhesion
Unattached proteins were removed from coated microplates by washing twice in 0.9% NaCl by plate inversion. Thereafter, 50 ml diluted PRP was added to each well together with soluble platelet activators and inhibitors. The platelet activators used were ADP and lysophosphatidic acid (LPA) from Sigma-Aldrich (St Louis, Missouri, USA), adrenaline from Merck NM AB (Stockholm, Sweden) and ristocetin from Diagnostica Stago (Asniè ressur-Seine, France). This study aimed to investigate the adhesive mechanisms by using drugs and antibodies that inhibits platelet function in different ways. The inhibit-ing drugs used were cangrelor (P2Y12-antagonist also called AR-C69931MX, which was a kind gift from The Medicines Company, Parsippany, New Jersey, USA) and MRS2179 (P2Y1-antagonist), BM-531 (combined TPreceptor antagonist and thromboxane synthase inhibitor) and indomethacin (cyclooxygenase inhibitor) from Sigma-Aldrich. Antibodies used were AK7 (anti-a 2 b 1 ), AK2 (anti-GPIb-IX-V), PM6/13 (anti-a IIb b 3 ), PM6/248 (anti-a IIb b 3 ) and W3/25 (negative isotype control) from AbD Serotec (Oxford, UK) as well as the therapeutic a IIb b 3 -antagonists abciximab (Centocor B.V., Leiden, The Netherlands), tirofiban (Merck Sharp & Dohme B.V., Haarlem, The Netherlands) and eptifibatide (Glaxo Operations UK Ltd, Durham, UK). To maximize the effects of cangrelor, BM-531 or indomethacin, diluted PRP was preincubated with these substances before addition to the wells unless otherwise stated. Initial experiments with the antibodies indicated that preincubation was not necessary, and the antibodies were therefore added directly to the wells. In addition, as Mg 2þ can affect the levels of platelet adhesion to all surfaces tested in this study [15, 20] , addition of PRP and platelet activators/inhibitors was performed both in the presence or absence of 5 mmol/l MgCl 2 . The final volume of PRP mixed with activators/inhibitors was 100 ml in each well, regardless of the platelet inhibitors used or whether MgCl 2 was present or not. The microplates were then left at room temperature (RT) for 1 h in order to allow platelet attachment to the surfaces.
Spectrophotometric detection of adhered platelets
Adhesion of platelets was performed as described above, and unattached platelets were removed by washing twice in 0.9% NaCl by plate inversion. One hundred and forty microlitres of a sodium citrate/citric acid buffer (0.1 mol/l, pH 5.4) containing 0.1% Triton X-100 and 1 mg/ml p-nitrophenyl-phosphate (Sigma-Aldrich) was then added to all wells. On a separate microplate, 140 ml of the sodium citrate/citric acid buffer was mixed with 50 ml 0.9% NaCl or 50 ml diluted PRP. These wells served as measures of 0 and 100% platelet adhesion. Background absorbance was measured at 405 nm using a Spectramax microplate reader (Molecular Devices, Sunnyvale, California, USA). This was performed for all microplates, including the microplate measuring 0 and 100% adhesion. The microplates were then incubated for 40 min in RT during constant shaking. This incubation allowed the occurrence of an enzymatic reaction between added p-nitrophenyl-phosphate and platelet acid phosphatase, which resulted in a soluble product. After the 40-min incubation, 100 ml of 2 mol/l NaOH was added to all wells, which stopped the reaction and resulted in a change of colour of the developed product. The microplates were then subjected to another absorbance measurement at 405 nm. Background absorbance was subtracted, and percentage adhesion was calculated.
Platelet visualization with fluorescence microscopy Adhesion of platelets was performed as described above, and unattached platelets were removed by washing twice in 0.9% NaCl by plate inversion. Fifty microliters (6.3 mg/ ml) of antifibrinogen-fluorescein isothiocyanate (FITC) (Diapensia, Linkö ping, Sweden) was added followed by incubation for 20 min at RT. The microplates were then manually washed two times in phosphate-buffered saline (PBS) followed by addition of 4% paraformaldehyde. After incubation for 10 min in RT, the microplates were once again washed manually two times with PBS followed by addition of 50 ml of 0.1% Triton X-100. The microplates were then incubated for 5 min in RT, washed manually twice with PBS and platelets were stained for actin by addition of 50 ml (66 nmol/l) of Alexa fluor 546 Phalloidin (Invitrogen Corporation, Carlsbad, California, USA). After incubation for 20 min in RT, the microplates were washed manually twice with PBS followed by microscopical examination using a Zeiss AxioObserverinverted fluorescence microscope.
Statistics
Statistical analyses were performed as either paired t-tests or repeated measures analysis of variance (ANOVA) followed by Dunnett's or Bonferroni's posthoc tests. Results were considered significant at the P value of less than 0.05. The concentration of cangrelor that inhibited 50% of ADP-induced adhesion (IC 50 ) was calculated from sigmoidal dose-response curves developed by nonlinear regression using GraphPad Prism 
Results
Adhesion to fibrinogen, in the presence of 5 mmol/l MgCl 2 , was significantly inhibited by the a IIb b 3 -antibody PM6/248 and by the a IIb b 3 -inhibiting drugs abciximab, eptifibatide and tirofiban ( Fig. 1a and b ). However, adhesion to fibrinogen was not affected by the antibody PM6/13, which is also directed against a IIb b 3 (not shown). Neither the negative isotype-control W3/25 nor the a 2 b 1antibody AK7 affected platelet adhesion to fibrinogen ( Fig. 1a ). AK7 was used at 10 mg/ml, which was enough to significantly inhibit platelet adhesion to collagen (see below). Furthermore, the GPIb-IX-V-antibody AK2 induced a small but significant increase in platelet adhesion to fibrinogen (mean adhesion for solvent was 14.1% compared with 17.9% for adhesion in the presence of 40 mg/ml AK2, P < 0.01, n ¼ 4, not shown). Platelet adhesion to collagen, in the presence of 5 mmol/l MgCl 2 , was significantly inhibited by the antibody AK7 directed towards a 2 b 1 (Fig. 2a ). The a IIb b 3 -inhibitors abciximab (10 mg/ml), eptifibatide (1 mg/ml) and tirofiban (1 mg/ml) had minor but significant inhibiting effects on platelet adhesion to collagen (Fig. 2b) . The concentrations chosen for abciximab, eptifibatide and tirofiban were used as they resulted in maximal block of adhesion to fibrinogen ( Fig. 1b ). Elevating their concentrations to 40 mg/ml did not increase the inhibiting effects on platelet adhesion to collagen (not shown). Furthermore, adhesion to collagen was neither affected by the a IIb b 3 -antibodies PM6/13 (not shown) and PM6/248 ( Fig. 2a ) nor by the negative isotype-control W3/25 ( Fig. 2a ) or by AK2 directed against GPIb-IX-V (not shown).
We have earlier reported adhesion of activated platelets to albumin [15, 16] and confirm these findings in this study by using ADP (Fig. 3a) , as well as adrenaline alone or in combination with ristocetin (Table 1) , as platelet activators. We next wanted to investigate the receptor Platelet adhesion to proteins in microplates Eriksson and Whiss 199 Platelet adhesion to fibrinogen. Platelet adhesion to fibrinogen was inhibited by the a IIb b 3 -antibody PM6/248 (a, n ¼ 6) and the a IIb b 3inhibitors abciximab, eptifibatide and tirofiban (b, n ¼ 4) but not by the a 2 b 1 -antibody AK7 (a). W3/25, which is an isotype-control antibody for PM6/248 and AK7, had no effect on platelet adhesion (a Fig. 3a , with the albumin surface, were performed both in the presence (n ¼ 2) and absence (n ¼ 2) of externally added Mg 2þ . All patients showed obvious dependence on a IIb b 3 indicating that this receptor is important for adhesion to albumin independently of Mg 2þ levels. In a similar way, adhesion to fibrinogen in the presence of ADP and Mg 2þ was inhibited by PM6/ 248, abciximab, eptifibatide and tirofiban but not by the a 2 b 1 -antibody AK7 or the negative isotype-control W3/25 (Fig. 3b ). We also investigated the receptor dependency for ADP-induced adhesion to collagen. As presence of Mg 2þ has a large impact on basal platelet adhesion to collagen [15] , we investigated ADP-induced adhesion to collagen both in the presence and absence of Mg 2þ . Adhesion in the presence of 5 mmol/l MgCl 2 was inhibited by the a 2 b 1 -antibody AK7 as well as by PM6/248 and abciximab directed against a IIb b 3 but not by W3/25, AK2, eptifibatide and tirofiban ( Fig. 3c ). Furthermore, AK7 but not PM6/248, AK2 or W3/25 inhibited ADP-induced platelet adhesion in the absence of Mg 2þ (not shown). Initial experiments with cangrelor, which is an antagonist of the ADP-binding P2Y12-receptor, were aimed at investigating relevant doses of this compound for inhibition of ADP-dependent adhesion. Thus, for this purpose, we wanted to use surfaces in which platelet adhesion is distinctly increased by ADP. This criterion was met in the absence of Mg 2þ for albumin and collagen.
Cangrelor was found to effectively reduce ADP-induced platelet adhesion on both surfaces. IC 50 values for inhibition of platelet adhesion induced by 1 and 10 mmol/l ADP were 1.2 and 9.2 nmol/l on albumin ( Fig. 4a ) and 0.26 and 2.5 nmol/l on collagen ( Fig. 4b ). Adhesion was completely inhibited at 0.1 mmol/l ( Fig. 4a and b ), and this concentration was therefore used in all further experiments. We also compared the effect of cangrelor with the effect of MRS2179, which antagonizes the ADP-receptor P2Y1. These experiments were performed without preincubation and showed that 10 mmol/l MRS2179 was able to induce a significant decrease in platelet adhesion to albumin and collagen induced by 10 mmol/l ADP (insets of Fig. 4a and b ). For both surfaces, adhesion induced by 10 mmol/l ADP was significantly lower in the presence of 0.1 mmol/l cangrelor compared with 100 mmol/l MRS2179 (P < 0.01 on collagen, P < 0.001 on albumin). We further studied the effect of cangrelor on adhesion to albumin, collagen and fibrinogen in the presence of different activating stimuli (Table 1) . Beyond platelet adhesion induced by ADP, activating stimuli such as collagen, ristocetin, adrenaline as well as adrenaline combined with ristocetin were significantly dependent on ADP for inducing platelet adhesion. However, the data show great differences in ADP dependency for different activators with smallest effects of cangrelor occurring when stimulating platelets with adrenaline or ristocetin alone ( Table 1) .
We further wanted to establish the role of released TXA 2 in this platelet adhesion assay. For this, we used BM-531, which is a combination of TP-receptor antagonist and thromboxane synthase inhibitor [21] . Investigating platelet adhesion to albumin, collagen and fibrinogen in the presence of ADP, adrenaline or ristocetin showed that BM-531 induced small but significant effects at 10 mmol/l ( Table 1) . The adhesion to a collagen surface without Mg 2þ induced by the combination of adrenaline and ristocetin was not affected by BM-531. However, we wanted to further clarify the possible TXA 2 dependency for this stimulus by using the cyclooxygenase inhibitor Platelet adhesion to collagen. Platelet adhesion to collagen was inhibited by the a 2 b 1 -antibody AK7 (a, n ¼ 6), the a IIb b 3 -inhibiting drugs abciximab, eptifibatide and tirofiban (b, n ¼ 6) but not by the a IIb b 3antibody PM6/248 (a). W3/25, which is a negative isotype-control antibody for PM6/248 and AK7, had no effect on platelet adhesion (a). Numerals in brackets indicate concentration in mg/ml. Stars and NS indicate difference compared with solvent. Data are presented as means þ SEM. Ã P < 0.05, ÃÃ P < 0.01, NS, not significant. Adhesion of activated platelets. Platelet adhesion to albumin (a) induced by 10 mmol/l ADP was inhibited by the a IIb b 3 -inhibitors abciximab, eptifibatide, tirofiban and PM6/248 but not by the a 2 b 1 -antibody AK7 or the GPIb-IX-V antibody AK2 (n ¼ 4). Similarly, platelet adhesion to fibrinogen (b) induced by 10 mmol/l ADP was inhibited by the a IIb b 3 -inhibitors abciximab, eptifibatide, tirofiban and PM6/248 but not by the a 2 b 1 -antibody AK7 (n ¼ 4). Platelet adhesion to collagen (c) induced by 10 mmol/l ADP was inhibited by the a IIb b 3 -inhibitors PM6/248 and abciximab and by the a 2 b 1 -antibody AK7 but not by eptifibatide, tirofiban or AK2. For all three surfaces, W3/25 (negative isotype control for AK2, AK7 and PM6/248) had no effect on platelet adhesion. Numerals in brackets indicate concentration in mg/ml. Stars and NS indicate difference compared with ADP-induced adhesion. Ã P < 0.05, ÃÃ P < 0.01, NS, not significant. Significant difference for ADP-induced adhesion compared with solvent is denoted by tilted squares (^)^^P < 0.01. All filled bars represent presence of 10 mmol/l ADP, whereas open bars represent basal adhesion. Data are presented as means þ SEM. The effects of 0.1 mmol/l cangrelor or 10 mmol/l BM-531 on platelet adhesion to albumin, collagen and fibrinogen were investigated in the absence (n ¼ 6 for cangrelor and n ¼ 8 for BM-531) or presence (n ¼ 6 for cangrelor and n ¼ 4 for BM-531) of different platelet-activating stimuli. The results are presented as mean percentage adhesion. Two values are shown in each column as the cangrelor (bold) and BM-531 (plain) experiments were performed on blood from separate donors followed by pairwise statistical analysis. Significantly decreased adhesion for cangrelor or BM-531 compared with control is indicated as M P < 0.05, MM P < 0.01 and MMM P < 0.001. Absence of stars means that the difference is not significant. Tilted squares (^P < 0.05,^^^P < 0.001) in the control columns show significantly increased platelet adhesion induced by platelet activators compared with solvent (analysis performed on combined data from the cangrelor and BM-531 experiments). Absence of tilted squares means lack of significantly increased platelet adhesion. All numerals associated with platelet activators describe concentration in mmol/l except for ristocetin in which the unit of concentration is mg/ml. Adr, adrenaline; ND, not determined; Risto, ristocetin.
indomethacin (10 mmol/l) instead of BM-531. We then found indomethacin to decrease adhesion from 19.7% (SEM ¼ 6.3) to 14.6% (SEM ¼ 3.4) (P < 0.01, n ¼ 4, not shown).
Complementary to the detection of adhered platelets by spectrophotometry, platelet adhesion was also investigated by fluorescence microscopy. Platelet adhesion, as visualized by fluorescence microscopy, appeared to correlate well with percentage adhesion as measured spectrophotometrically. It was also clear that adhered platelets were homogenously spread over the surface.
Representative examples of adhesion to albumin, collagen and fibrinogen are shown in Fig. 5 .
Discussion
The present study investigated the dependency on adhesion receptors and autocrine activation for platelet adhesion to albumin, collagen and fibrinogen in a static platelet adhesion assay (Fig. 6 ). Platelet adhesion to collagen was shown to be primarily dependent on the a 2 b 1 -receptor with a possible small contribution from a IIb b 3 . The dependence on both a 2 b 1 and a IIb b 3 for platelet adhesion to collagen has been observed earlier Platelets visualized by actin staining, attached to surfaces coated with albumin, collagen and fibrinogen. Adhesion to collagen was in the presence of 5 mmol/l MgCl 2 , whereas adhesion to albumin and fibrinogen was visualized in the absence of MgCl 2 . These conditions were chosen in order to facilitate adhesion to all surfaces, which would increase the likelihood of achieving measurable platelet adhesion. The respective images show basal platelet adhesion to albumin (a), adhesion to albumin in the presence of 10 mmol/l ADP (b), basal adhesion to collagen (c) and basal adhesion to fibrinogen (d). In parallel with the actin staining, a separate microplate was used for spectrophotometrical quantification of platelet adhesion. Corresponding adhesion values for the respective figures were 5.1% (for a), 15.6% (for b), 18.4% (for c), 26.9% (for d). Scale bars show the length of 50 mm. Schematic diagram summarizing the mechanisms investigated in the current study. The study focused on platelet adhesion to albumin, collagen and fibrinogen in a static assay. The purpose was to evaluate the dependency on adhesion receptors (GPIb-IX-V, a 2 b 1 , a IIb b 3 ) as well as autocrine activation (ADP, TXA 2 ) for adhesion to the protein surfaces in this specific assay. TXA 2 , thromboxane A 2 for isolated platelets [22] . The authors suggested that the effect of a IIb b 3 was derived from platelet aggregation. Although this is also possible in our study, platelet aggregation is probably of minor importance as the assay was performed during conditions known to restrict aggregation, such as avoidance of shaking [2] and presence of Mg 2þ [23] . Furthermore, surface characteristics are able to influence the structure of adsorbed proteins [24] [25] [26] and collagen might contain cryptic RGD sequences that could be exposed after degradation [27] . Consequently, it could be proposed that RGD sequences in collagen are exposed in this assay contributing to platelet adhesion. However, a IIb b 3 was probably of secondary importance as inhibition of platelet adhesion to collagen by a IIb b 3inhibitors was relatively weak and also not observed for all inhibitors. Furthermore, a 2 b 1 continued to be an important receptor for adhesion to collagen even after activating the platelets with ADP. The role of the GPVI receptor for platelet adhesion to collagen was not directly investigated in this study. However, we found that platelet adhesion to collagen was dependent on either externally added Mg 2þ or on addition of an external platelet activator such as ADP. The dependence on Mg 2þ further strengthens the conclusion that a 2 b 1 is the central receptor for platelet adhesion to collagen in this assay as a 2 b 1 is known to be Mg 2þ dependent [2] [3] [4] . Furthermore, adhesion to collagen in the absence of Mg 2þ was not observed unless ADP, or another activator, was added. This suggests that activation of a 2 b 1 and consequent adhesion to collagen can, in this specific assay, be induced by ADP (and possibly other platelet activators not tested in this study) but not by GPVI.
In the present assay, platelet adhesion to fibrinogen was strongly dependent on the a IIb b 3 -receptor. Irrespective of the presence or absence of ADP, there was no effect of the a 2 b 1 -antibody AK7 on platelet adhesion to fibrinogen. This suggests that activating a 2 b 1 with an external activator does not make it adhesive for fibrinogen. Among the a IIb b 3 -inhibitors, it was only PM6/13 that was without effect on platelet adhesion to fibrinogen. The absence of effect for the PM6/13 antibody is at first somewhat surprising as this antibody has been shown to inhibit both platelet adhesion [28] and platelet aggregation [29] . Unlike abciximab, eptifibatide, tirofiban [30] and, most probably, PM6/248 [28] , PM6/13 does not interact with RGD-binding epitope(s) [29] . Thus, we suggest that binding of RGD sequences is necessary for platelets to adhere to fibrinogen in this assay. A total dependence on RGD binding in this assay but not in others might explain the discrepancy with previous studies described above for PM6/13. Hornby et al. [31] showed PM6/248 to have a platelet-activating effect dependent on binding to both a IIb b 3 and to FcgRII. Regarding platelet aggregation, the activating effect was maximal at 8 mg/ml. Higher concentrations still resulted in platelet activation but did not result in aggregation suggesting stearic hindrance of fibrinogen binding. In our study, we found 40 mg/ml of PM6/248 to inhibit platelet adhesion to fibrinogen in accordance with inhibition of aggregation. However, we could not detect increased adhesion induced by PM6/248, neither by 40 mg/ml on a 2 b 1 -dependent adhesion to collagen nor by lower concentrations on fibrinogen (not shown). The discrepancy between the study by Hornby et al. and ours is likely due to assay differences as potent inhibition of platelet adhesion to fibrinogen by PM6/248 can only occur if external Mg 2þ is present.
Platelet adhesion to albumin only occurs in the presence of externally added platelet activators. We have earlier shown that platelet adhesion to albumin in the presence of LPA and adrenaline in this assay is mediated by a IIb b 3 [16] . In this study we investigated the receptors that may be important for the adhesion of platelets activated with ADP. There was a striking resemblance between the results obtained on albumin and the results regarding adhesion to fibrinogen. AK2, AK7 and PM6/13 were without effect on both surfaces whereas PM6/ 248, abciximab, eptifibatide and tirofiban inhibited platelet adhesion to albumin as well as fibrinogen. First of all, inhibition observed with inhibitors of a IIb b 3 but not with a 2 b 1 -antibody or GPIb-IX-V-antibody shows that adhesion to albumin induced by ADP is mediated by a IIb b 3 . Furthermore, as PM6/13 was the only a IIb b 3inhibitor that was without effect, RGD is probably the binding site common for both surfaces. It is possible that albumin, upon binding to a surface, might change conformation and thereby allow adhesion through a IIb b 3 . It is also possible that fibrinogen is attached to the albumincoated wells, as earlier studies have shown that fibrinogen can interact with albumin [32] and that platelets in fact adhere to fibrinogen. Fibrinogen might be derived directly from plasma or it might be secreted from activated platelets. We suggest that direct or indirect interactions of platelets with albumin might be important in vivo as albumin is present in normal arteries [33] as well as in atherosclerotic plaques [34] .
The platelet adhesion assay is developed for measurement of the total amount of platelets attached to a surface. However, more information regarding the adhesive process could possibly be gained if it is combined with morphological evaluation of the adhered platelets. It has previously been shown that adhesion to fibrinogen, but not albumin, induces platelet spreading [35] . This might be important regarding our above discussion about platelet adhesion to an albumin-coated surface. We, therefore, made an effort to investigate the adhered platelets to both fibrinogen and albumin by fluorescence microscopy. The design of the 96-well microplates makes it difficult to retrieve images of high magnification. However, the visualization by actin staining clearly showed that platelets were homogenously attached on the surfaces and were not present in clusters. In addition, when evaluating the platelet images in parallel with percentage adhesion values obtained from the spectrophotometric measurements, we found good correlation between the assays. This confirms the accuracy of the spectrophotometric estimate of platelet adhesion.
Unlike other antibodies, the GPIb-IX-V-antibody AK2 did not inhibit adhesion to any of the surfaces investigated in this study. Even though vWf is present in the plasma milieu it is not surprising that AK2 was found to be without inhibiting effect in this assay as interactions between GPIb-IX-V and vWf are known to require flow conditions [8, 36] . Instead, we found the GPIb-IX-Vantibody to induce a small but significant increase in platelet adhesion to fibrinogen. It might therefore be possible that the interaction between the antibody and GPIb-IX-V induces intracellular activating events. Furthermore, ristocetin is an interesting compound in this experimental setting as it acts by inducing interactions between vWf and GPIb-IX-V [37] . AK2 was observed to decrease ristocetin-induced platelet adhesion to fibrinogen (P < 0.01, n ¼ 4) and to collagen (nonsignificant trend, n ¼ 4) towards the levels of basal adhesion (data not shown). There are two possible explanations for the effect of AK2 on ristocetin-induced adhesion. In the first scenario, AK2 inhibits platelet activation induced by the interaction between GPIb-IX-V and vWf-ristocetin [38] with the secondary consequence of decreased platelet adhesion. In the second scenario, AK2 acts as a direct inhibitor of platelet adhesion mediated by vWf bound to GPIb-IX-V. If the second scenario is true, this opens up the possibility of measuring GPIb-IX-V-dependent adhesion despite the absence of flow. The exact mechanism by which AK2 inhibits ristocetin-induced adhesion must be further investigated in future studies.
The initial experiments performed with cangrelor showed that this substance is very effective in inhibiting ADP-induced platelet adhesion. We have earlier shown that platelet adhesion to albumin induced by LPA combined with adrenaline is dependent on ADP [16] , which is most likely released from activated platelets. In this study, we antagonized ADP signalling with cangrelor and showed that ADP is important for several other adhesive interactions as well. Even though adhesion induced by adrenaline or ristocetin as single soluble activator was shown to be significantly inhibited by cangrelor, the effect was relatively weak and probably of no practical importance. However, platelet adhesion induced by simultaneous activation by adrenaline and ristocetin was markedly inhibited by cangrelor. These results suggest that ristocetin and adrenaline both have the capacity to induce ADP secretion on their own. However, when combined, they increase platelet adhesion synergistically, probably by inducing platelet secretion of ADP more effectively. Even though BM-531 significantly attenuated platelet adhesion for several of the adhesive interactions studied, the effects were very small. These results are in accordance with previous results using this assay showing marginal effects of high doses of acetylsalicylic acid (ASA) on platelet adhesion to collagen [15] . We also found that indomethacin could inhibit adhesion during conditions that were not affected by BM-531. Consequently, conclusions regarding the influence of TXA 2 on platelet adhesion in this assay may differ depending on the substance used for inhibiting TXA 2 signalling. Nevertheless, the moderate effects of both BM-531 and indomethacin suggest that release of TXA 2 probably has a relatively minor role for inducing adhesion in this assay.
In conclusion, adhesion to collagen was mainly dependent on the a 2 b 1 -receptor, whereas the a IIb b 3 -receptor was necessary for adhesion to fibrinogen. In addition, autocrine stimulation not only by ADP but also by TXA 2 seemed to be important for adhesion during several but not all conditions. Thus, the adhesive mechanisms occurring in the static platelet adhesion assay are in accordance with current knowledge regarding platelet activation. We, therefore, suggest that the static platelet adhesion assay, despite its simplicity, could generate valuable results regarding platelet activity. Depending on the extensiveness of the chosen protocol, an assay takes between 3 and 4 h to complete, and it might thus be used as a relatively fast screening device for investigating the effects of agonists or antagonists or both on platelet function. For instance, we show in this study that ADPinduced adhesion to albumin is dependent on a IIb b 3 . Such adhesive interactions of platelets and novel surfaces could easily be investigated by using the platelet adhesion assay. Future studies will, in addition to what has already been performed [18, 19] , investigate the clinical usefulness of the assay.
providing excellent help with the fluorescence microscopy experiments.
